Daiichi Sankyo Shares Fall 10% After Delay

Daiichi Sankyo shares fell nearly 10% to ¥2,505.5, hitting a four‑year low since March 2022.
The firm postponed its FY earnings release to May 11, citing review of oncology portfolio and loss‑provision estimates.
It also moved its five‑year business plan announcement to May 11 and recently sold its OTC unit to Suntory Holdings.
The delay occurs amid broader restructuring and focus on oncology drugs like Enhertu, co‑developed with AstraZeneca.